Hematoma, Subdural, Chronic
10
2
2
3
Key Insights
Highlights
Success Rate
50% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 65/100
30.0%
3 terminated out of 10 trials
50.0%
-36.5% vs benchmark
20%
2 trials in Phase 3/4
67%
2 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (10)
The Onyx™ Trial For The Embolization Of The Middle Meningeal Artery For Chronic Subdural Hematoma
Preventing Recurrences of Chronic Subdural Hematoma in Adult Patients by Middle Meningeal Artery Embolization
Exhaustive Drainage Versus Fixed-time Drainage for Chronic Subdural Hematoma After One-burr Hole Craniostomy
Tranexamic Acid to Prevent OpeRation in Chronic Subdural Hematoma
Covers to Improve Esthetic Outcome After Surgery for Chronic Subdural Hematoma
The Role of Meningeal Lymphatic Vessels in the Absorption of Chronic Subdural Hematoma and Its Injury Mechanism
Curcumin/Turmeric as a Treatment for Patients With Subdural Hematomas Recurrence
Chronic Subdural Hematoma - Reduction of Recurrence by Treatment With Angiotensin Converting Enzyme Inhibitors
Irrigation of Chronic Subdural Hematomas - is More Better?
Role of Dexamethasone in the Conservative Treatment of Chronic Subdural Hematoma